Previous 10 | Next 10 |
home / stock / mkgaf / mkgaf news
2023-12-07 23:57:14 ET Summary MoonLake Therapeutics is a clinical-stage biopharmaceutical company developing nanobody-based therapies for inflammatory diseases. Their lead product candidate, Sonelokimab, has shown best-in-class potential in treating Hidradenitis suppurativa and P...
2023-12-06 10:11:00 ET More on TG Therapeutics TG Therapeutics: Trying To Fill The Gap Back To $20 TG Therapeutics, Inc. (TGTX) Q3 2023 Earnings Call Transcript TG Therapeutics: Q3 Earnings Spike Hard To Explain Given Rival's Numbers TG Therapeutics gains aft...
2023-12-06 04:37:12 ET More on Merck KGaA Merck KGaA (MKGAF) Q3 2023 Earnings Call Transcript Merck KGaA: Company With A Potential Upside Exscientia climbs as Merck KGaA joins AI drug discovery Historical earnings data for Merck KGaA Dividend scorecar...
2023-11-12 20:42:37 ET Summary Evotec SE's appeal is based on its valuation and upside potential in the drug discovery and development sector. The company's financial performance is average, with negative margins and subpar business model specifics for 2022. Despite some issue...
2023-11-09 14:07:10 ET Merck KGaA (MKGAF) Q3 2023 Earnings Conference Call November 09, 2023, 08:00 ET Company Participants Constantin Fest - Head, IR Belen Garijo - Chair & CEO Helene von Roeder - CFO Kai Beckmann - CEO, Electronics Peter Guenter - C...
2023-11-09 06:56:14 ET More on Merck KGaA Merck KGaA: Company With A Potential Upside Merck KGaA: Expect A 10% CAGR EBITDA Increase In 2024-2025 Exscientia climbs as Merck KGaA joins AI drug discovery Historical earnings data for Merck KGaA Dividend s...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
2023-11-05 02:15:00 ET Summary Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for its next-gen PARP1 inhibitor to Germany’s Merck KGaA. BioLineRx, an Israeli biotech, out-licensed China rights to a stem cell mobilizer for multiple myeloma and stem cell disease...
2023-11-01 04:47:30 ET Summary Merck KGaA is an undervalued pharma company with a long history and strong fundamentals. The company has above-average margins and a diverse business portfolio in healthcare, life sciences, and electronics. Despite a conservative dividend yield, ...
2023-10-16 12:27:11 ET Summary Sartorius is facing challenging business conditions due to destocking and delayed customer investment. The company's ability to maintain high levels of sustained growth is a concern due to increasing competition and financing costs. We downgrade ...
News, Short Squeeze, Breakout and More Instantly...
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...